(Notices) NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION
|
|
- Adelia Short
- 6 years ago
- Views:
Transcription
1 EN Official Journal of the European Union C 361/1 IV (Notices) NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union s on marketing authorisations in respect of medicinal s from 1 September 2015 to 30 September 2015 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council ( 1 )) (2015/C 361/01) ( 1 ) OJ L 136, , p. 1.
2 C 361/2 EN Official Journal of the European Union Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted INN (International Non-Proprietary Name) Holder of the marketing authorization Pharmaceutical form ATC code (Anatomical Therapeutic Chemical Code) Ivabradine Anpharm ivabradine ANPHARM Przedsiębiorstwo Farmaceutyczne S.A. ul. Annopol 6B, Warszawa, Polska EU/1/15/1041 Film-coated tablet C01EB Raxone idebenone Santhera Pharmaceuticals (Deutschland) GmbH Marie-Curie Strasse 8, Lörrach, Deutschland EU/1/15/1020 Film-coated tablet N Pemetrexed Lilly pemetrexed Eli Lilly Nederland B.V. Grootslag 1-5, NL RA Houten, Nederland EU/1/15/1034 Intravenous use L01BA Intuniv guanfacine Shire Pharmaceuticals Ireland Limited 5 River Walk, Citywest Business Campus, Dublin 24, Ireland EU/1/15/1040 Prolonged-release tablet C02AC
3 EN Official Journal of the European Union C 361/3 INN (International Non-Proprietary Name) Holder of the marketing authorization Pemetrexed Sandoz pemetrexed Sandoz GmbH Biochemiestrasse 10, A-6250 Kundl, Österreich Zalviso Sufentanil Grünenthal GmbH Zieglerstrasse 6, D , Aachen, Deutschland Zerbaxa ceftolozane/tazobactam Fexeric ferric citrate coordination complex Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Keryx Biopharma UK Ltd Riverbank House, 2 Swan Lane, London, EC4R 3TT, United Kingdom Praluent alirocumab Sanofi-Aventis groupe 54 rue La Boétie, F Paris, France Pharmaceutical form ATC code (Anatomical Therapeutic Chemical Code) EU/1/15/1037 Powder for concentrate for solution for infusion L01BA EU/1/15/1042 Sublingual tablet N01AH EU/1/15/1032 Powder for concentrate for solution for infusion J01DI EU/1/15/1039 Film-coated tablet V03AE EU/1/15/1031 Solution for injection C
4 C 361/4 EN Official Journal of the European Union Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted ATryn GTC Biotherapeutics UK Limited 10 Norwich Street, London EC4A 1BD, United Kingdom Daklinza Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, Ebixa H. Lundbeck A/S Ottiliavej 9, DK-2500 Valby, Danmark Enbrel Pfizer Limited Ramsgate Road, Sandwich, Kent CT13 9NJ, Esbriet Roche Registration Limited 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, Extavia Novartis Europharm Limited Grastofil Apotex Europe B.V. Darwinweg 20, NL CR Leiden, Nederland Hirobriz Breezhaler Novartis Europharm Limited Plegridy Biogen Idec Limited Innovation House, 70 Norden Road, Maidenhead, Berkshire SL6 4AY, Xofigo Bayer Pharma AG D Berlin, Deutschland Xyrem UCB Pharma Ltd 208 Bath Road, Slough, Berkshire SL1 3WE, ADCETRIS Takeda Pharma A/S Dybendal Alle 10, 2630 Taastrup, Danmark Betmiga Astellas Pharma Europe B.V. Sylviusweg 62, NL-2333 BE Leiden, Nederland Elaprase Shire Human Genetic Therapies AB Svärdvägen 11D, SE Danderyd, Sverige Quinsair Aptalis Pharma SAS Route de Bû, F Houdan, France EU/1/06/ EU/1/14/ EU/1/02/ EU/1/99/ EU/1/11/ EU/1/08/ EU/1/13/ EU/1/09/ EU/1/14/ EU/1/13/ EU/1/05/ EU/1/12/ EU/1/12/ EU/1/06/ EU/1/14/
5 EN Official Journal of the European Union C 361/ Evoltra Genzyme Europe B.V. Gooimeer 10, NL-1411 DD Naarden, Nederland EU/1/06/ Iclusig ARIAD Pharma Ltd Riverbridge House, Guildford Road, Leatherhead, Surrey KT22 9AD, EU/1/13/ Imvanex Bavarian Nordic A/S Hejreskovvej 10a, DK-3490 Kvistgaard, Danmark EU/1/13/ INOmax Linde Healthcare AB SE Lidingö, Sverige EU/1/01/ Metalyse Boehringer Ingelheim International GmbH Binger Straße 173, D Ingelheim am Rhein, Deutschland EU/1/00/ Perjeta Roche Registration Limited 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, EU/1/13/ Ruconest Pharming Group N.V. Darwinweg 24, NL-2333 CR Leiden, Nederland EU/1/10/ Sebivo Novartis Europharm Limited EU/1/07/ Spedra Menarini International Operations Luxembourg S.A. 1 avenue de la Gare, L-1611 Luxembourg, Grand-Duché de Luxembourg EU/1/13/ TachoSil Takeda Austria GmbH St.-Peter-Strasse 25, A-4020 Linz, Österreich EU/1/04/ Visudyne Novartis Europharm Limited EU/1/00/ Ilaris Novartis Europharm Limited EU/1/09/ Inflectra Hospira UK Limited Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, EU/1/13/ Toviaz Pfizer Limited Ramsgate Road, Sandwich, Kent CT13 9NJ, EU/1/07/
6 C 361/6 EN Official Journal of the European Union Trajenta Boehringer Ingelheim International GmbH Binger Straße 173, D Ingelheim am Rhein, Deutschland Viagra Pfizer Limited Ramsgate Road, Sandwich, Kent CT13 9NJ, Arixtra Aspen Pharma Trading Limited 3016 Lake Drive Citywest Business Campus Dublin 24 Ireland Iasibon Pharmathen S.A. 6 Dervenakion, Pallini Attiki, Ελλάδα Sifrol Boehringer Ingelheim International GmbH Binger Straße 173, D Ingelheim am Rhein, Deutschland Vibativ Clinigen Healthcare Limited Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire DE14 2WW, EU/1/11/ EU/1/98/ EU/1/02/ EU/1/10/ EU/1/97/ EU/1/11/ Withdrawal of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) Biograstim AbZ-Pharma GmbH Graf-Arco-Straße 3, D Ulm, Deutschland EU/1/08/
7 EN Official Journal of the European Union C 361/7 Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted INN (International Non-Proprietary Name) Holder of the marketing authorization Pharmaceutical form ATC code (Anatomical Therapeutic Chemical Code) FORTEKOR PLUS pimobendan/benazepril Elanco Europe Ltd Lilly House, Priestley Road, Basingstoke, Hampshire, RG 24 9NL, United Kingdom Novaquin meloxicam Le Vet Beheer B.V. Wilgenweg 7, NL TV Oudewater, Nederland Vectormune ND Cell-associated live recombinant turkey herpes virus (rhvt/ ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain CEVA-Phylaxia Co. Ltd Budapest, Szállás u. 5, 1107 MAGYAR- ORSZÁG EU/2/15/185 Tablet QC09BX EU/2/15/186 Oral suspension QM01AC EU/2/15/188 Suspension and solvent for suspension for injection QI01AD
8 C 361/8 EN Official Journal of the European Union Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted BTVPUR AlSap 1 Merial 29 avenue Tony Garnier, F Lyon, France BTVPUR AlSap 1-8 Merial 29 avenue Tony Garnier, F Lyon, France Meloxoral Le Vet B.V. Wilgenweg 7, NL-3421 TV Oudewater, Nederland Onsior Elanco Europe Ltd Lilly House, Priestley Road, Basingstoke, Hampshire, RG 24 9NL, EU/2/10/ EU/2/10/ EU/2/10/ EU/2/08/ Anyone wishing to consult the public assessment report on the medicinal s in question and the s relating thereto is invited to contact: The European Medicines Agency 7, Westferry Circus, Canary Wharf UK LONDON E14 4H
Official Journal of the European Union C 401/3
28.12.2012 Official Journal of the European Union C 401/3 Summary of European Union s on marketing authorisations in respect of medicinal s from 1 November 2012 to 30 November 2012 (Published pursuant
More informationEuropean Medicines Agency decision
EMA/75416/2018 European Medicines Agency decision P/0042/2018 of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel), (EMEA-000567-PIP01-09-M05)
More informationEUROPEAN MEDICINES AGENCY DECISION. of 22 September 2009
European Medicines Agency Doc. Ref. EMEA/583696/2009 P/190/2009 EUROPEAN MEDICINES AGENCY DECISION of 22 September 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral
More informationEuropean Medicines Agency decision
EMA/342140/2013 European Medicines Agency decision P/0151/2013 of 5 July 2013 on the acceptance of a modification of an agreed paediatric investigation plan for voriconazole (Vfend), (EMEA-000191-PIP01-08-M05)
More informationPUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 15 June 1999 EMEA/18046/99 PUBLIC STATEMENT ON TROVAN / TROVAN IV / TURVEL / TURVEL IV (Trovafloxacin/Alatrofloxacin)
More informationEuropean Medicines Agency decision
EMA/43440/2014 European Medicines Agency decision P/0046/2014 of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (EMEA- 000498-PIP01-08-M02)
More informationEuropean Medicines Agency decision
EMA/741983/2016 European Medicines Agency decision P/0324/2016 of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)
More informationEuropean Medicines Agency decision
EMA/232938/2014 European Medicines Agency decision P/0102/2014 of 2 May 2014 on the acceptance of a modification of an agreed paediatric investigation plan for corifollitropin alfa (Elonva) (EMEA-000306-PIP01-08-M02)
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationEuropean Medicines Agency decision
EMA/247674/2011 European Medicines Agency decision P/95/2011 of 4 April 2011 on the granting of a product specific waiver for ezetimibe/simvastatin (Inegy and associated names) (EMEA-000006-PIP02-10) in
More informationEuropean Medicines Agency decision
EMA/757980/2016 European Medicines Agency decision P/0313/2016 of 21 December 2016 on the agreement of a paediatric investigation plan for complex of povidone and iodine / dexamethasone (SHP640) (EMEA-001936-PIP01-16)
More informationEuropean Medicines Agency decision
EMA/501292/2014 European Medicines Agency decision P/0227/2014 of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for aliskiren (Rasilez and associated names),
More informationEuropean Medicines Agency decision
EMA/436977/2012 European Medicines Agency decision P/0141/2012 of 23 July 2012 on the granting of a product specific waiver for ezetimibe / simvastatin (Inegy and associated names) (EMEA-000006-PIP03-12)
More information(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationEuropean Medicines Agency decision
EMA/738885/2013 European Medicines Agency decision P/0005/2014 of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP03-10-M02)
More informationEuropean Medicines Agency decision
EMA/776083/2014 European Medicines Agency decision P/0001/2015 of 7 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M04)
More informationEuropean Medicines Agency decision
EMA/738884/2013 European Medicines Agency decision P/0004/2014 of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for bevacizumab (Avastin), (EMEA-000056-PIP01-07-M02)
More informationEuropean Medicines Agency decision
EMA/470611/2010 European Medicines Agency decision P/122/2010 of 26 July 2010 on the acceptance of a modification of an agreed paediatric investigation plan for lisdexamfetamine dimesylate, (EMA-000553-PIP01-09-M01)
More informationEuropean Medicines Agency decision
EMA/107989/2012 European Medicines Agency decision P/0038/2012 of 24 February 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral for modified Vaccinia Ankara - Bavarian
More informationPRAC recommendations on signals
3 October 2013 EMA/PRAC/550442/2013 Pharmacovigilance Risk Assessment Committee Adopted at the PRAC meeting of 2-5 September 2013 This document provides an overview of the recommendations adopted by the
More informationEUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008
European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationEuropean Medicines Agency decision
EMA/182693/2012 European Medicines Agency decision P/0061/2012 of 28 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for Ezetimibe (Ezetrol and associated names),
More informationEuropean Medicines Agency decision
EMA/285017/2012 European Medicines Agency decision P/0105/2012 Of 4 June 2012 on the acceptance of a modification of an agreed paediatric investigation plan for tiotropium bromide (monohydrate) (Spiriva
More information(Notices) NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION
29.6.2018 EN Official Journal of the European Union C 229/1 IV (Notices) NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union s on marketing
More informationEuropean Medicines Agency decision
EMA/137097/2017 European Medicines Agency decision P/0073/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/434825/2017 European Medicines Agency decision P/0235/2017 of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for venetoclax (Venclyxto), (EMEA-002018-PIP02-16)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR suspension for injection for sheep and cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1
More informationEuropean Medicines Agency decision
EMA/585513/2013 European Medicines Agency decision P/0249/2013 of 18 October 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral for tedizolid (phosphate) (EMEA-001379-PIP01-12)
More informationPRAC recommendations on signals
22 February 2018 EMA/PRAC/59224/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 5-8 February 2018 PRAC meeting This document provides an overview of the recommendations adopted by
More information(Notices) NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION
23.2.2018 EN Official Journal of the European Union C 70/1 IV (Notices) NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Summary of European Union s on marketing
More informationEuropean Medicines Agency decision
EMA/662557/2012 European Medicines Agency decision P/0254/2012 of 22 October 2012 on the acceptance of a modification of an agreed paediatric investigation plan for riociguat, (EMEA- 000718-PIP01-09-M02)
More informationEuropean Medicines Agency decision
EMA/731087/2017 European Medicines Agency decision P/0341/2017 of 16 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin
More informationEuropean Medicines Agency decision
EMA/273931/2014 European Medicines Agency decision P/0137/2014 of 11 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ cells transduced with
More informationMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP)
25 June 2010 corr. 1 Press Office Press release Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2010 Positive opinions for new medicines adopted The Committee
More informationEuropean Medicines Agency decision
EMA/717745/2013 European Medicines Agency decision P/0312/2013 of 19 December 2013 on the acceptance of a modification of an agreed paediatric investigation plan for aciclovir (Sitavig and associated names)
More informationEuropean Medicines Agency decision
EMA/279562/2017 European Medicines Agency decision P/0129/2017 of 8 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Split influenza virus, inactivated containing
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 Karvezide 150/12.5 mg tablets Irbesartan/hydrochlorothiazide PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TO TAKE YOUR TABLETS Your doctor has prescribed this medicine for you.
More informationPRAC recommendations on signals
14 December 2017 EMA/PRAC/610978/2017 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 27-30 November 2017 PRAC meeting This document provides an overview of the recommendations adopted
More informationEuropean Medicines Agency decision
EMA/802543/2012 European Medicines Agency decision P/0293/2012 of 18 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for prucalopride (Resolor), (EMEA-000459-PIP01-08-M02)
More informationEuropean Medicines Agency decision
EMA/848760/2017 European Medicines Agency decision P/0033/2018 of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M10)
More informationMember State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State Marketing Authorisation
More informationEuropean Medicines Agency decision
EMA/319518/2014 European Medicines Agency decision P/0146/2014 of 13 June 2014 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11-M01)
More informationEuropean Medicines Agency decision
EMA/586558/2013 European Medicines Agency decision P/0266/2013 of 30 October 2013 on the agreement of a paediatric investigation plan for autologous CD34+ cells transduced with lentiviral vector containing
More informationANNEX II A. MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
ANNEX II A. MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OF THE MARKETING AUTHORISATION 1 A. MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE Name and
More informationEuropean Medicines Agency decision
EMA/23029/2016 European Medicines Agency decision P/0022/2016 of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dabrafenib (Tafinlar), (EMEA-001147-PIP01-11-M03)
More informationPRAC recommendations on signals
17 December 2015 EMA/PRAC/788914/2015 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the PRAC meeting of 30 November - 3 December 2015 This document provides an overview of the recommendations
More informationEuropean Medicines Agency decision
EMA/585994/2013 P/0270/2013 of 30 October 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for eptacog alfa (activated) (EMEA-001382-PIP01-12) in accordance with
More informationEUROPEAN MEDICINES AGENCY DECISION. of 24 June 2008
European Medicines Agency Doc. Ref. EMEA/310181/2008 P/32/2008 EUROPEAN MEDICINES AGENCY DECISION of 24 June 2008 on the application for agreement of a Paediatric Investigation Plan for zoledronic acid
More informationEuropean Medicines Agency decision
EMA/463568/2010 European Medicines Agency decision P/133/2010 of 28 July 2010 on the refusal of a paediatric investigation plan and on the granting of a waiver for omalizumab, (Xolair) (EMEA-000735-PIP01-09)
More informationEuropean Medicines Agency decision
EMA/654883/2017 European Medicines Agency decision P/0312/2017 of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (EMEA- 001418-PIP01-13-M01)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Proteq West Nile suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. InductOs 12 mg kit for implant dibotermin alfa
PACKAGE LEAFLET: INFORMATION FOR THE USER InductOs 12 mg kit for implant dibotermin alfa Read all of this leaflet carefully before you are given this medicine. Keep this leaflet. You may need to read it
More informationEuropean Medicines Agency decision
EMA/761887/2015 European Medicines Agency decision P/0307/2015 of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib (EMEA- 001123-PIP01-11-M03)
More informationList of nationally authorised medicinal products
10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London
More informationEuropean Medicines Agency decision
EMA/398442/2016 European Medicines Agency decision P/0191/2016 of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11-M03)
More informationEuropean Medicines Agency decision
EMA/281879/2015 European Medicines Agency decision P/0097/2015 of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human
More informationEuropean Medicines Agency decision
EMA/155875/2015 European Medicines Agency decision P/0062/2015 of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M09)
More informationQuality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro
Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices
More informationPACKAGE INSERT. Marketing authorisation holder Boehringer Ingelheim Vetmedica GmbH Ingelheim/Rhein Germany
B. PACKAGE INSERT PACKAGE INSERT 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for dogs 2. STATEMENT OF THE ACTIVE AND OTHER SUBSTANCE(S) Meloxicam 5 mg/ml 3. NAME
More informationEuropean Medicines Agency decision
EMA/106209/2017 European Medicines Agency decision P/0074/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/348027/2017 European Medicines Agency decision P/0166/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for aciclovir (Sitavig and associated names),
More informationEuropean Medicines Agency decision
EMA/113206/2013 European Medicines Agency decision P/0067/2013 of 26 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,
More informationPRAC recommendations on signals
3 April 2018 1 EMA/PRAC/136563/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 5-8 March 2018 PRAC meeting This document provides an overview of the recommendations adopted by the
More informationEuropean Medicines Agency decision
EMA/730065/2010 European Medicines Agency decision P/1/2011 of 3 January 2011 on the acceptance of a modification of an agreed paediatric investigation plan for adalimumab (Humira) (EMEA-000366-PIP01-08-M03)
More informationEuropean Medicines Agency decision
EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for
More informationANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
ANNEX I ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 4 A. MANUFACTURING AUTHORISATION HOLDERS Manufacturers
More informationEUROPEAN MEDICINES AGENCY DECISION. of 15 July 2009
European Medicines Agency Doc. Ref. EMEA/387961/2009 P/136/2009 EUROPEAN MEDICINES AGENCY DECISION of 15 July 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/501874/2008 European Medicines Agency decision P/0303/2016 of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationEuropean Medicines Agency decision
EMA/392193/2014 European Medicines Agency decision P/0206/2014 of 8 August 2014 on the agreement of a paediatric investigation plan for captopril (EMEA-001544-PIP01-13) in accordance with Regulation (EC)
More informationEuropean Medicines Agency decision
EMA/482989/2013 European Medicines Agency decision P/0209/2013 of 3 September 2013 on the agreement of a paediatric investigation plan for glibenclamide, (EMEA-001324-PIP01-12) in accordance with Regulation
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 2 PACKAGE LEAFLET Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
More informationEuropean Medicines Agency decision
EMA/38339/2017 European Medicines Agency decision P/0021/2017 of 3 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA- 001501-PIP02-13-M02)
More informationEuropean Medicines Agency decision
EMA/202840/2012 European Medicines Agency decision P/0072/2012 of 24 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (EMEA-000769-PIP01-09-M02)
More informationEuropean Medicines Agency decision
EMA/590275/2014 European Medicines Agency decision P/0275/2014 of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat), (EMEA-000402-PIP02-11-M01)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equip WNV emulsion for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationLegal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS
Legal Supplement Part B Vol. 57, No. 6 18th January, 2018 11 LEGAL NOTICE NO. 5 REPUBLIC OF TRINIDAD AND TOBAGO FOOD AND DRUGS ACT, CHAP. 30:01 NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS ISSUED
More informationEUROPEAN MEDICINES AGENCY DECISION. of 11 August 2009
European Medicines Agency Doc. Ref. EMEA/420697/2009 P/160/2009 EUROPEAN MEDICINES AGENCY DECISION of 11 August 2009 on the granting of a product specific waiver for testosterone (Intrinsa) (EMEA-000571-PIP01-09)
More informationEuropean Medicines Agency decision
EMA/714398/2010 European Medicines Agency decision P/229/2010 of 23 November 2010 on the acceptance of a modification of an agreed paediatric investigation plan for rosuvastatin (calcium) (Crestor and
More informationEuropean Medicines Agency decision
EMA/565636/2017 European Medicines Agency decision P/0282/2017 of 4 October 2017 on the granting of a product specific waiver for ramucirumab (Cyramza), (EMEA-002074-PIP01-16) in accordance with Regulation
More informationMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP)
22 July 2011 EMA/CHMP/557552/2011 corr* 1 Press Office Press release Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2011 Positive opinions for new medicines
More informationEuropean Medicines Agency decision
EMA/785816/2015 European Medicines Agency decision P/0294/2015 of 3 December 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/797044/2013 European Medicines Agency decision P/0040/2014 of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (EMEA- 001119-PIP02-12-M01)
More informationPackage leaflet: Information for the user. Spinraza 12 mg solution for injection. nusinersen
Package leaflet: Information for the user Spinraza 12 mg solution for injection nusinersen This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
More informationPackage leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa
Package leaflet: Information for the user Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa Read all of this leaflet carefully before you start using this medicine because
More informationLondon, 24 January 2000 EMEA/1952/00
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 24 January 2000 EMEA/1952/00 EMEA PUBLIC STATEMENT ON ABACAVIR (Ziagen) IMPORTANT SAFETY INFORMATION
More informationInformation and Notices
Official Journal of the European Union ISSN 1725-2423 C 184 English edition Information and Notices Volume 54 24 June 2011 Notice No Contents Page IV Notices NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES,
More informationPRAC recommendations on signals
14 September 2017 EMA/PRAC/407007/2017 Corr 1 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 29 August-1 September 2017 PRAC meeting This document provides an overview of the recommendations
More informationEuropean Medicines Agency decision
EMA/10910/2014 European Medicines Agency decision P/0013/2014 of 22 January 2014 on the acceptance of a modification of an agreed paediatric investigation plan for aluminium hydroxide adsorbed, depigmented
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ZULVAC 8 Ovis suspension for injection for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 2 ml of
More informationEUROPEAN MEDICINES AGENCY DECISION. of 22 December 2009
European Medicines Agency Doc. Ref. EMA/816085/2009 P/252/2009 EUROPEAN MEDICINES AGENCY DECISION of 22 December 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for
More informationMember State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing autorisation Holder
More informationEuropean Medicines Agency decision
EMA/757977/2016 European Medicines Agency decision P/0364/2016 of 21 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for KEOC liquid extract ethanolic 30 per
More informationCOMMISSION IMPLEMENTING DECISION. of XXX
EUROPEAN COMMISSION Brussels, XXX SANTE/11331/2017 (POOL/E3/2017/11331/11331-EN.doc) [ ](2017) XXX draft COMMISSION IMPLEMENTING DECISION of XXX renewing the authorisation for the placing on the market
More informationEuropean Medicines Agency decision
EMA/666038/2017 European Medicines Agency decision P/0323/2017 of 31 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris), (EMEA-000876-PIP05-15-M02)
More informationInformation and Notices
Official Journal of the European Union ISSN 1977-091X C 56 English edition Information and Notices Volume 55 24 February 2012 Notice No Contents Page IV Notices NOTICES FROM EUROPEAN UNION INSTITUTIONS,
More informationANNEX III LABELLING AND PACKAGE LEAFLET ANNEX
ANNEX III LABELLING AND PACKAGE LEAFLET ANNEX B. PACKAGE LEAFLET 2 NAME OF THE MEDICINAL PRODUCT OLANSEK 2.5 mg TABLETS (OLANZAPINE) GENERAL ADVICE Please read this information carefully before you start
More information